Lonza Expands Pharma & Biotech Footprint Increasing its Drug Product Services
Lonza announced today that its Pharma & Biotech segment is expanding its footprint for Parenteral Dosage Form development with a further build-out of its Drug Product Services (DPS). This investment will significantly expand both capability and capacity of DPS at the Stücki Science Park in Basel (CH) and will create more than 50 new positions. The expanded offering includes new capabilities for drug product process development.
DPS opened its laboratories in November 2016 with an initial focus on Formulation Development and Drug Product Analytical Development. This facility was recently granted a GMP license after a successful audit by Swissmedic allowing QC release and stability testing of drug products.
This significant expansion represents an important milestone in Lonza’s evolution to become a fully integrated drug development partner. With the recent acquisition of Capsugel, combined with DPS’s excellence in parenterals, we offer a wide range of services to meet our customers' drug product needs," said Marc Funk, COO of Lonza's Pharma & Biotech segment. "Our expansion in Basel also signals Lonza's strong commitment to the local community."
The DPS team provides a holistic approach to drug product development that anticipates and prevents problems early and helps ensure the product is optimal for manufacture, supply chain and patient use. The DPS team provides a complete portfolio of services for parenteral dosage forms including products for injection and infusion for intravenous, subcutaneous, and intraocular routes of administration.
These offerings also include specialized services, such as:
• Particulate identification, characterization and quantification
• Excipient and surfactant characterization
• Extractables and leachables assessment
• Container closure integrity testing
“The expansion of Drug Product Services reflects the value that Lonza brings to our pharma and biotech customers through exceptional experience, a strong scientific track record and state-of-the-art instrumental infrastructure which enables them to accelerate and de-risk Drug Product development and commercialization,” said Prof Dr. Hanns-Christian Mahler, Lonza’s Head of Drug Product Services.
This article has been republished from materials provided by Lonza. Note: material may have been edited for length and content. For further information, please contact the cited source.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
APC Protein Deletion Disrupts Cell Signalling and Could Cause AutismNews
Researchers show deletion of the protein APC in progenitor cells leads to massive disruption of brain development and a signaling cascade previously linked to genes associated with autism.READ MORE
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE